Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms

Journal of Neurochemistry

Volumn 69, Issue 1, 1997, Pages 206-213

  Prosperini, Elena ^a   Rizzi, Massimo ^a   Fumagalli, Fabio ^a,b   Tarizzo, Gianluca ^a   Samanin, Rosario ^a   Bendotti, Caterina ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b DUKE UNIVERSITY   (United States)

Author keywords

5 Hydroxytryptamine uptake inhibitors; Basal ganglia; Citalopram; Obsessive compulsive disorder; Somatostatin

Indexed keywords

CITALOPRAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE TIME EFFECT RELATION; DRUG BRAIN LEVEL; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OBSESSION; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

ANIMALIA;

EID: 0030942750     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69010206.x     Document Type: Article

References (42)

1. Altemus M., Pigott T., L'Heureux F., Davis C. L., Rubinow D. R., Murphy D. L., and Gold P. W. (1993) CSF somatostatin in obsessive-compulsive disorder. Am. J. Psychiatry 150, 460-464.
2. Baxter L., Phelps M., and Mazziotti J. (1987) Local cerebral glucose metabolic rates of obsessive compulsive disorder compared to unipolar depression and normal controls. Arch. Gen. Psychiatry 44, 211-218.
3. Beal M. F. and Martin J. B. (1983) Effect of lesions on somatostatin-like immunoreactivity in the rat striatum. Brain Res. 266, 67-73.
4. Beal M. F. and Martin J. B. (1984) Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity. Neurosci. Lett. 47, 125-130.
5. Bendotti C., Hohmann C., Forloni G., Reeves R., Coyle J. T., and Oster-Granite M. L. (1990) Developmental expression of somatostatin in mouse brain. II. In situ hybridization. Dev. Brain Res. 53, 26-39.
6. Bendotti C., Tarizzo G., Fumagalli F., Baldessari S., and Samanin R. (1993) Increased expression of preproneuropeptide Y and preprosomatostatin mRNA in striatum after selective serotoninergic lesions in rats. Neurosci. Lett. 160, 197-200.
7. Bennett G. W., Edwardson J. A., Marcano de Cotte D., Berelowitz M., Pimstone B. L., and Kronheim S. (1979) Release of somatostatin from rat synaptosomes. J. Neurochem. 32, 1127-1130.
8. Bissette G. and Myers B. (1992) Somatostatin in Alzheimer's disease and depression. Life Sci. 51, 1389-1410.
9. Bonanno G., Parodi B., Cafaggi S., and Raiteri M. (1991) Somatostatin release from rat cerebral cortex synaptosomes. J. Neurochem. 57, 1258-1264.
10. Chen N.-H. and Reith M. E. A. (1994) Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships. J. Neurochem. 63, 1701-1713.
11. Dawbarn D., DeQuidt M. F., and Emson P. C. (1985) Survival of basal ganglia neuropeptide Y/somatostatin neurones in Huntington's disease. Brain Res. 340, 251-260.
12. Doran A. R., Rubinow D. R., Wolkowitz O. M., Roy A., Breier A., and Pickar D. (1989) Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA. Biol. Psychiatry 25, 431-439.
13. Ennis C., Kemp J. D., and Cox B. (1981) Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J. Neurochem. 36, 1515-1520.
14. Epelbaum J. (1986) Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol. 27, 63-100.
15. Goodman W. K., Price L. H., Delgado P. L., Palumbo J., Krystal J. H., Nagy L. M., Rasmussen S. A., Heninger G. R., and Charney D. S. (1990) Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparison of fluvoxamine and desipramine. Arch. Gen. Psychiatry 47, 577-585.
16. Greist J. H., Jefferson J. W., Kobak K. A., Katzelnick D. J., and Serlin R. C. (1995) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch. Gen. Psychiatry 52, 53-60.
17. Hanokoglu I., Tanese N., and Fuchs E. (1983) Complementary DNA sequence of human cytoplasmic actin. Interspecies divergence of 3′ non coding regions. J. Mol. Biol. 163, 673-678.
18. Hyttel J. (1977) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology 51, 225-233.
19. Insel T. R. and Zohar J. (1987) Psychopharmacologic approaches to obsessive-compulsive disorder, in Psychopharmacology: The Third Generation of Progress (Meltzer H. Y., ed), pp. 1205-1210. Raven Press, New York.
20. Invernizzi R., Bramante M., and Samanin R. (1995) Extracellular concentrations of serotonin in the dorsal hippocampus after acute and chronic treatment with citalopram. Brain Res. 696, 62-66.
21. Johansson O., Hökfelt T., and Elde R. P. (1984) Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. Neuroscience 13, 265-339.
22. Johnson A. M. (1991) The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals, in Selective Serotonin Re-uptake Inhibitors (Feighner J. P. and Boyer W. F., eds), pp. 37-70. John Wiley & Sons, Chichester.
23. Kakigi T. and Maeda K. (1992) Effect of serotonergic agents on regional concentrations of somatostatin-and neuropeptide Y-like immunoreactivities in rat brain. Brain Res. 599, 45-50.
24. Kakigi T., Maeda K., Kaneda H., and Chihara K. (1992) Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J. Affect. Disord. 25, 215-220.
25. Luxenberg J. S., Flament M., Swedo S., Rapoport J., and Rapoport S. (1988) Neuroanatomic abnormalities in obsessive-compulsive disorder detected in quantitative x-ray computed tomography. Am. J. Psychiatry 145, 1089-1094.
26. Masseroli M., Messori A., Bendotti C., Ponti M., and Forloni G. (1993) Automatic quantitative evaluation of autoradiographic band films by computerized image analysis. Life Sci. 53, 331-336.
27. Mathé A. A., Nomikos G. G., and Svensson T. H. (1993) In vivo release of somatostatin from rat hippocampus and striatum. Neurosci. Lett. 149, 201-204.
28. McDougle J. C., Goodman W. K., Price L. H., Delgado P. L., Krystal J. H., Charney D. S., and Heninger G. R. (1990) Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry 147, 652-654.
29. Melzacka M., Rurak A., Adamus A., and Daniel W. (1984) Distribution of citalopram in the blood serum and in the central nervous system of rats after single and multiple dosage. Pol. J. Pharmacol. Pharm. 36, 675-682.
30. Palkovits M. and Brownstein M. J. (1985) Distribution of neuropeptides in the central nervous system using biochemical micro-methods, in Handbook of Chemical Neuroanatomy. Vol. 4: GABA and Neuropeptides in the CNS, Part I (Bjorklund A. and Hokfelt T., eds), pp. 1-92. Elsevier Science Publishers B. V., Amsterdam.
31. Palkovits M., Kobayashi R., Brown M., and Vale W. (1980) Changes in hypothalamic, limbic and extrapyramidal somatostatin levels following various hypothalamic transections in rat. Brain Res. 195, 499-505.
32. Prosperini E., Samanin R., and Bendotti C. (1995) Effect of acute and chronic treatment with citalopram on somatostatin levels in different brain regions of the rat. Pharmacol. Res. 31 (Suppl.), 283.
33. Radke J. M., Spyraki C., and Thermos K. (1993) Neuronal release of somatostatin in the rat striatum: an in vivo microdialysis study. Neuroscience 54, 493-498.
34. Rapoport J. L. and Wise S. P. (1988) Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol. Bull. 24, 380-384.
35. Rubinow D. R. (1986) Cerebrospinal fluid somatostatin and psychiatric illness. Biol. Psychiatry 21, 341-365.
36. Spampinato U., Esposito E., and Samanin R. (1985) Serotonin agonists reduce dopamine synthesis in the striatum only when impulse flow of nigro-striatal neurons is intact. J. Neurochem. 45, 980-982.
37. Sperk G. and Widmann R. (1985) Somatostatin precursor in the rat striatum: changes after local injection of kainic acid. J. Neurochem. 45, 1441-1447.
38. Stanford S. C. (1996) Prozac: panacea or puzzle? Trends Pharmacol. Sci. 17, 150-154.
39. Strieder G. and Sperk G. (1989) Purification and characterization of prosomatostatin from rat brain. J. Neurochem. 53, 346-353.
40. Thai L. J., Laing K., Horowitz S. G., and Makman M. K. (1986) Dopamine stimulates rat cortical somatostatin release. Brain Res. 372, 205-209.
41. Vezzani A., Monno A., Rizzi M., Galli A., Barrios M., and Samanin R. (1992) Somatostatin release enhanced in the hippocampus of partially and fully kindled rats. Neuroscience 51, 41-46.
42. Weiss L. T. and Chesselet M. F. (1989) Regional distribution and regulation of preprosomatostatin messenger RNA in the striatum, as revealed by in situ hybridization histochemistry. Mol. Brain Res. 5, 121-130.